The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey
- 28 August 2008
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 14 (5) , 923-930
Abstract
Summary. Prophylaxis is standard of care for boys with severe haemophilia A. Indications for prophylaxis in adulthood, non‐severe haemophilia A, haemophilia B and haemophilia with inhibitors are less well defined. This survey, conducted in 2006, aimed to describe prophylaxis use in patients of all ages and severities with haemophilia A or haemophilia B in Canada. Data on 2663 individuals (2161 haemophilia A; 502 haemophilia B), including 78 inhibitor‐positive patients, were returned by 22/25 Canadian haemophilia treatment centres. This represented 98% of the Canadian haemophilia population. Frequency of prophylaxis use, defined as infusion of factor VIII/IX concentrate at least once weekly for ≥45 weeks of the year, was highest in individuals with severe haemophilia A (69%). It was lower in individuals with severe haemophilia B (32%), moderate haemophilia A (18%) or B (5%) and mild haemophilia A (1%) or B (1%). Among individuals with severe haemophilia A, the frequency of prophylaxis use was 84% in children (≤18 years) and 55% in adults (>18 years). Thirteen per cent of inhibitor‐positive individuals were receiving prophylaxis with bypassing agents. Comparison with data obtained from a 2002 Canadian survey showed a greater use of prophylaxis in children ≤5 years of age with severe haemophilia A (73% vs. 49%). Prophylaxis is no longer confined to children with severe haemophilia A, but is used in a significant proportion of adults with severe haemophilia A and individuals with severe haemophilia B or moderate haemophilia A. Prophylaxis is being started earlier in boys with severe haemophilia A.Keywords
This publication has 23 references indexed in Scilit:
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Prophylaxis in adults with haemophiliaHaemophilia, 2007
- Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome dataHaemophilia, 2007
- Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor responseHaemophilia, 2007
- Prophylactic treatment with activated prothrombin complex concentrate (FEIBA®) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitorsHaemophilia, 2007
- The international immune tolerance study: a multicenter prospective randomized trial in progressJournal of Thrombosis and Haemostasis, 2006
- Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis StudyJournal of Thrombosis and Haemostasis, 2006
- Evidence for the benefits of prophylaxis in the management of hemophilia AThrombosis and Haemostasis, 2006
- Can long‐term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the NetherlandsBritish Journal of Haematology, 2005
- Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and BJournal of Internal Medicine, 1992